This explains why treatment with anti TNF is effective to reverse the process of ventricular dilatation only when administered in the early stage, and the apparent contradiction of the worsening of the clinical condition induced by biological therapy with anti-TNF in patients with advanced CHF39. This evidence concerns the gene TNF and Ventriculomegaly.